Background
Quality-of-life analysis from EORTC 22952-26001 (Kocher 2011). 359 patients with 1–3 brain metastases after resection/SRS randomized to WBRT vs observation. This QoL paper used QLQ-C30, EQ-5D, and mini-mental state exam (MMSE) data. Primary QoL endpoint: global health status at 9 months post-randomization (patients progression-free at 9 months).
Interventions and follow up
Arm A: Adjuvant WBRT 30 Gy/10 fr after resection or SRS
Arm B: Observation after resection or SRS
Primary endpoint: Global health status at 9 months (in patients without intracranial recurrence)
mFollow up: QoL assessed at 8 weeks, 6 months, 9 months, 12 month
Arm B: Observation after resection or SRS
Primary endpoint: Global health status at 9 months (in patients without intracranial recurrence)
mFollow up: QoL assessed at 8 weeks, 6 months, 9 months, 12 month
Results
Global health status at 9 months (no recurrence): Significantly worse with WBRT (mean difference -9.4, P=.04)
Physical function at 9 months (no recurrence): Worse with WBRT (mean diff -9.5, P=.04)
QoL in patients with intracranial recurrence: Better with WBRT (protection from recurrence-related decline)
MMSE: No significant difference overall
Physical function at 9 months (no recurrence): Worse with WBRT (mean diff -9.5, P=.04)
QoL in patients with intracranial recurrence: Better with WBRT (protection from recurrence-related decline)
MMSE: No significant difference overall
Adverse events
Main adverse events: Fatigue and alopecia during WBRT significantly worse. Longer-term QoL significantly impaired at 9 months in patients who remained progression-free on WBRT — suggesting direct WBRT-related harm rather than disease progression.
Conclusions
Among patients without intracranial recurrence at 9 months, adjuvant WBRT was associated with significantly worse QoL and physical functioning compared with observation — attributable to direct WBRT toxicity. Among those with recurrence, WBRT slightly protected QoL. Overall, these data supported omitting WBRT in patients after complete local treatment, accepting the trade-off of higher intracranial recurrence for better QoL.
Key Limitations
Key Limitations: Only patients alive and progression-free at 9 months are included in the primary QoL analysis — these are a selected (better prognosis) subgroup. MMSE is an insensitive measure of subtle cognitive decline. Standard WBRT doses (30 Gy/10 fr) without hippocampal sparing or memantine — modern HA-WBRT may mitigate some of the harm observed. QoL instruments not specifically designed for radiation neurotoxicity assessment.
Clinical Context
Soffietti 2013 provided the first prospective QoL evidence that WBRT causes measurable QoL decline beyond disease-related symptoms. Together with MMSE-based cognitive testing from other trials, this supports individualized decision-making: WBRT improves brain control but impairs QoL in patients who don't recur (the majority after effective SRS). For patients at high risk of recurrence or with many lesions, the QoL trade-off may be acceptable.
References